18th Feb 2005 07:00
Provalis PLC18 February 2005 For Immediate Release 18th February 2005 Provalis plc Board Changes Appointment of Dr Alan Aikman, and retirement of Dr David Bloxham, as Non-Executive Directors Provalis plc (LSE: PRO; NASDAQ: PVLS), the International Medical Diagnostics andPharmaceuticals Group, is pleased to announce that it appointed Dr Alan Aikmanas a non-executive Director on 17th February 2005. Dr Aikman, aged 57, an experienced Healthcare business consultant, is currentlya non-executive director of both listed and unlisted Healthcare companies. Heis a non-executive director of Theratase plc and is the non-executive Chairmanof Niagara Healthcare Ltd and Vibrant Medical Ltd. He has also been anexecutive Director of Smith and Nephew Healthcare and Palmer Bio-Science Ltd. DrAikman, who has a Ph.D in biochemistry, began his career in marketing andpharmaceutical product management at GD Searle both in the UK and USA. At the same time, Dr David Bloxham announced that he will retire from the Boardon 31st May 2005, after five years with the Company. David's insight has provedinvaluable in helping Provalis to focus, and then successfully partner, thevaccine business and to develop its US sales strategy for the MedicalDiagnostics business that has now been implemented. Frank Harding, Chairman of Provalis, said, "I welcome this opportunity ofthanking David for his significant contribution to the Group's strategicdevelopment and wish him well for the future. At the same time, I am delighted to welcome Alan to the Board. His internationalmarketing and commercial experience in a broad range of Healthcare businesseswill be invaluable to Provalis as it expands the direct marketing and sale ofits products in world markets." END Provalis' Website; http://www.provalis.com "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Statements in this announcement that relate to future plans, expectations,events, performances and the like are forward-looking statements as defined inthe US Private Securities Litigation Reform Act of 1995. Actual results ofevents could differ materially from those described in the forward-lookingstatements due to a variety of factors. Such factors include, among others: theviability of the Group's products, which are at various stages of development;the generation of sufficient operating cash flow by the Group's pharmaceuticaland medical diagnostic businesses to finance the ongoing development of thesebusinesses as well as the Group's research and development activities; thesuccess of the Group's research and development strategy and activities;uncertainties related to future clinical trial results and the associatedregulatory process; the execution and success of collaborative agreements withthird parties; availability and level of reimbursement for the Group's productsfrom government health administration authorities or other third-party payors;the rate of net cash utilisation within the Group and, hence, the Group'spossible need for additional capital in the short, medium and/or long term; theGroup's intellectual property position and the success of patent applicationsfor its products and technologies; the Group's dependence on key personnel;general business and economic conditions; the impact of future laws, regulationsand policies; stock market trends in the Group's sector; and other factorsbeyond the Group's control that may cause the Group's available capitalresources to be used more quickly than expected. These and other factors thatcould affect the Company's future results are more fully described in itsfilings with the US Securities and Exchange Commission, in particular the latest20-F filing, copies of which are available from the Company Secretary at theCompany's registered address. For further information:- Dr Phil Gould, Chief Executive Officer, Provalis plc Tel: 01244 833463Mr Peter Bream, Finance Director, Provalis plc Tel: 01244 833552Mr Lee Greenbury, Company Secretary, Provalis plc Tel: 01244 833402Lisa Baderoon, Buchanan Communications Tel: 020 7466 5000 Notes to Editors Provalis plc (LSE: PRO; NASDAQ: PVLS) is an international healthcare group withtwo operating businesses:- • Medical Diagnostics - develops medical diagnostic products for chronic disease management for sale to world markets. The business' principal products are in2it(TM) A1c and Glycosal(R), both diabetes diagnostic tests, and Osteosal(R), a diagnostic test for osteoporosis. • Pharmaceuticals - sells and markets its own, and third party, branded, prescription medicines in the UK and Ireland to GPs and hospitals through its regionally managed sales force. The business' principal product is Diclomax(R), a medicine for use in the treatment of musculo-skeletal disorders, and it also sells products in the areas of osteoporosis, migraine and dermatology. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Proservice Bldg